Development of a multitarget therapy for prostate cancer
Maria J. Ruiz Echevarría, PhD
Tuesday, April 19, 2022
Tweet
Transcript
Embed
Email
Bookmark
<<
<
>
>>
Tweet
Facebook
Email
Chapters
Introduction
CONTRIBUTIONS/DISCLOSURES
Prostate Cancer is the second leading cause of cancer related deaths in men
Androgen Receptor (AR) Signaling is essential for Prostate Cancer
Prostate Cancer Progression
Targeting Androgen Receptor Signaling
Therapeutic approach: Targeting multiple AR-coregulators
Death Induced by Survival gene Elimination (DISE)
Androgen Network (AN)-DISE
Therapeutic approach: Targeting multiple AR-coregulators AN-DISE
Identification/selection of shRNAs that are significantly depleted (toxic) from the cell culture
Toxic sh/siRNA validation
Toxic siRNAs decrease growth of cellular models of advanced Prostate Cancer (CRPC)
Toxic siRNAs minimally affect growth/viability of benign prostate cell lines
RNA-Seq analysis indicates that toxic shRNAs inhibit androgen signaling and other essential pathways
Summary and Conclusions
THANK YOU
No transcript for this webinar
More Info
Request info